|
檢驗結果的解讀 |
本檢測利用基因體定序(次世代定序)的方法,定序141個血癌常見基因(ABL1,
ADA, ANKRD26, ASXL1, ASXL2, ATM, ATRX, BCL6, BCOR, BCORL1,
BCR, BIRC3, BLM, BRAF, BRCA1, BRCA2, BRINP3, C17orf97, CALR,
CARD11, CBL, CBLB, CBLC, CDKN2A, CEBPA, CHEK2, CREBBP,
CRLF2, CSF1R, CSF3R, CTCF, CUX1, DAXX, DDX41, DNM2, DNMT1,
DNMT3A, EED, EGFR, ELANE, EP300, ETNK1, ETV6, EZH2, FAM154B,
FAM47A, FAS, FBXW7, FLRT2, FLT3, GATA1, GATA2, GJB3, GNAS,
HNRNPK, HRAS, IDH1, IDH2, IKZF1, IKZF3, IL7R, JAK1, JAK2,
JAK3, KAT6A, KCNA4, KCNK13, KDM6A, KDR, KIT, KLHDC8B, KLHL6,
KMT2A, KMT2C, KRAS, LRRC4, LUC7L2, MAP2K1, MLH1, MPL, MSH2,
MSH6, MYC, MYD88, NBN, NF1, NOTCH1, NPAT, NPM1, NRAS, NSD1,
NTRK3, OR13H1, OR8B12, P2RY2, PAX5, PCDHB1, PDGFRA, PHF6,
PML, PMS2, PRAMEF2, PRF1, PRPF40B, PRPF8, PTEN, PTPN11,
RAD21, RB1, RELN, RUNX1, SETBP1, SF1, SF3A1, SF3B1, SH2B3,
SH2D1A, SMARCB1, SMC1A, SMC3, SRP72, SRSF2, STAG2, STAT3,
STXBP2, SUZ12, TAL1, TERC, TERT, TET2, TNFRSF13B, TP53, TPMT,
TUBA3C, U2AF1, U2AF2, WAS, WRN, WT1, XPO1, ZRSR2),這些基因與血癌的形成、治療及預後有關,檢測結果除了可做為用藥治療的指南外,其中病人特有的突變,將可作為病人預後的標記,這樣的標記將比傳統以蛋白質的標記更具特異性,而且更加敏感及精準。 |